Options in Hypersensitivity Reactions to Chemotherapeutics
- 43 Downloads
Purpose of review
Chemotherapeutic drugs still represent a gold standard for the treatment of neoplastic disease. They can induce hypersensitivity reactions and are the third leading cause of fatal drug-induced anaphylaxis in the USA. This article has tried to highlight and summarize the most recent scientific progress concerning risk factors, pathogenesis, diagnosis, and treatment of these reactions.
Identification of patients at high risk of developing hypersensitivity reactions allows risk stratification to guide clinical decision-making. Therefore, the most recent researches evaluated the possibility to perform risk stratification in case of hypersensitivity reactions to platinum compounds and taxanes. In addition, new data are now available regarding the role of in vitro test for the diagnosis of reactions to platins and the role of drug provocation test in case of hypersensitivity to a number of chemotherapeutics. However, actually, the allergological work-up includes a very careful anamnesis of the patient and the characteristics of reaction, whereas skin tests are useful only for few classes of chemotherapy, namely platinum salts and probably taxanes. Premedication, desensitization and, in some cases, skin tests are able to prevent the majority of hypersensitivity reactions, permitting the administration of the most effective therapy.
Clearly, more studies are needed to better understand, diagnose, treat, and prevent these reactions. To reach this aim, a multidisciplinar approach to the cancer patient with potential allergies is needed.
KeywordsChemotherapy hypersensitivity Drug allergy Platinum compound hypersensitivity Taxane hypersensitivity Asparaginase hypersensitivity Desensitization
Compliance with Ethical Standards
Conflict of Interest
Mauro Pagani declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLellan MJ. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA. 1984;4(251):2255–61.CrossRefGoogle Scholar
- 2.World Health Organization available on www.who.int/cancer.
- 4.Donehower RC, Abeloff MD, Perry MC. Chemotherapy. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical Oncology. New York: Churchill Livingstone; 1996.Google Scholar
- 9.National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Published date May 28, 2009.Google Scholar
- 19.• Wang AL, Patil SU, Long AA, Banerji A. Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Ann Allergy Asthma Immunol. 2015;115:422–8. This paper evidences the optimal treatment of patients with severe HSRs to platins.CrossRefPubMedGoogle Scholar
- 24.Forcello NP, Khubchandani S, Patel SJ, et al. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review. J Oncol Pharm Pract. 2015 Apr;21(2):148–56.Google Scholar
- 33.Galindo-Rodríguez G, Jaime-Pérez JC, Salinas-Carmona MC, Gonzales-Diaz SN, Castro-Corona A, Cavazos-Gonzales R, et al. Do immunoglobulin G and immunoglobulin E anti-l-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study. Rev Bras Hematol Hemoter. 2017;39(3):202–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.•• Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, Ureña-Tavera A, Zamora-Verduga M, Lopez-Gonzalez P, et al. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy. 2015;10:784–94. In this paper rhe role of drug provocation test was evaluated for the first time in a wide number of patients.CrossRefGoogle Scholar
- 49.Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999 Apr;17(4):1141.Google Scholar
- 51.Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:1–11.Google Scholar
- 63.Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68:853–61.CrossRefPubMedGoogle Scholar
- 64.• Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1:494–500. Evaluate the role of in vitro tests in the diagnosis and management of HSRs to platinum compounds.CrossRefPubMedGoogle Scholar
- 68.Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002 Mar;84(3):378–82.Google Scholar
- 75.Kintzel PE. Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother. 2001;30:367–71.Google Scholar
- 77.•• Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016;137(4):1154–64. This paper evidences the important role of skin tests in the diagnosis and risk.strtifications of patients with HSRs to taxanes.CrossRefPubMedGoogle Scholar
- 78.Chen FC, Wang LH, Zheng XY, Zhang XM, Zhang J, Li LJ. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions. Oncotarget. 2017;8:19,236–43.Google Scholar
- 88.Avramis VI, Avramis EV, Hunter W, Long MC. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res. 2009;29:299–302.PubMedGoogle Scholar